Rebion provides a “Window to the Brain” to identify and help manage life-altering diseases that manifest from functional impairment in the brain.

Based on years of research and trials at major medical institutions, Rebion is commercializing the breakthrough Neural Performance Scanning (NPS) to identify and help manage life-altering diseases that manifest from functional impairments in the brain. NPS portable point-of-care devices provide previously unavailable information for fast and impactful triage, making early disease detection, intervention and customized treatment more accessible.

 What is NPS?

Using proprietary retinal scanning to quantify bilateral fixation and saccadic movement, NPS measures the neurophysiologic mechanism of the optic nerve/brain continuum, instantly identifying impairments.

 NPS for Lazy Eye

Rebion’s first commercial product is the blinq.® vision scanner, the first and only device FDA cleared to detect amblyopia and strabismus (lazy eye), is a transformative device that in just seconds measures eye fixation to detect lazy eye, the leading cause of pediatric vision loss and the #1 cause of monocular vision in loss in adults 20 to 70 years of age.

NPS for Visual Tracking Impairments

Currently in pivotal clinical trials, Rebion’s Traq.™ device looks for physical and structural disruptions within the brain-eye pathway. This previously unavailable measurement of the brain/retina/eye continuum may provide an objective assessment of the neurophysiological mechanisms tied to impairments.